nach oben

Diabetologia

Erschienen in:

01.06.2008 | For Debate

Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l

verfasst von: G. Van den Berghe

Erschienen in: Diabetologia | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Excerpt

Hyperglycaemia has been repeatedly associated with risk of mortality and morbidity in the intensive care unit (ICU). However, establishing a causal relationship between hyperglycaemia and adverse outcome requires randomised controlled trials assessing the impact of treating/preventing hyperglycaemia in this condition. The only two randomised controlled studies that have addressed this question so far targeted normoglycaemia (4.4–6.1 mmol/l) in ICUs and showed that the link indeed appears causal. The evidence currently available is thus in favour of a ‘normal ≤6.1 mmol/l’ level for blood glucose control in ICUs and is not supportive of J. Miles’s viewpoint in this debate [1], as studies on any other level have not been performed. …

Miles J, McMahon MM, Isley WL (2007) No, the glycaemic target in the critically ill should not be ≤6.1 mmol/l. Diabetologia DOI 10.1007/s00125-007-0888-5

Van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRef

Van den Berghe G, Schoonheydt K, Becx P et al (2005) Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64:1348–1353PubMed

Van den Berghe G, Wouters PJ, Kesteloot K et al (2006) Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 34:612–616PubMed

Ingels C, Debaveye Y, Milants I et al (2006) Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care and quality of life. Eur Heart J 27:2716–2724PubMedCrossRef

Krinsley JS (2004) Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79:992–1000PubMedCrossRef

Krinsley JS, Jones RL (2006) Cost analysis of intensive glycemic control in critically ill adult patients. Chest 129:644–650PubMedCrossRef

Brunkhorst FM, Kuhnt E, Engel C et al (2005) Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia—results from a randomized multicenter study (VISEP). Infection 33 (Suppl 1):19 (abstract)

Kompetenznetz Sepsis. Available from http://webanae.med.uni-jena.de/WebObjects/DSGPortal.woa/WebServerResources/sepnet/visep.html, accessed 22 December 2006

10.

National Institutes of Health: Glucontrol study: comparing the effects of two glucose control regimens by insulin in intensive care unit patients. Available from http://www.clinicaltrials.gov/ct/show/NCT00107601 and http://www.glucontrol.org/, accessed 22 December 2006

11.

Van den Berghe G, Wilmer A, Hermans G et al (2006) Intensive insulin therapy in medical intensive care patients. N Engl J Med 354:449–461PubMedCrossRef

12.

Hermans G, Wilmer A, Meersseman W et al (2007) Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 175:480–489PubMedCrossRef

13.

Van den Berghe G, Wilmer A, Milants I et al (2006) Intensive insulin therapy in mixed medical/surgical ICU: benefit versus harm. Diabetes 55:3151–3159PubMedCrossRef

14.

Furnary AP, Gao G, Grunkemeier GL et al (2003) Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:1007–1021PubMedCrossRef

15.

Furnary AP, Wu Y (2006a) Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract 12:22–26PubMed

16.

Furnary AP, Wu Y (2006b) Eliminating the diabetic disadvantage: the Portland Diabetic Project. Semin Thorac Cardiovasc Surg 18:302–308PubMedCrossRef

17.

Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512–1515PubMed

18.

Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H (1996) Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 17:1337–1344PubMed

19.

Scott JF, Robinson GM, French JM et al (1999) Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 30:793–799PubMed

20.

Ellger B, Debaveye Y, Vanhorebeek I et al (2006) Survival benefits of intensive insulin therapy in critical illness. Impact of normoglycemia versus glycemia-independent actions of insulin. Diabetes 55:1096–1105PubMedCrossRef

21.

Van den Berghe G, Wouters PJ, Bouillon R et al (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31:359–366PubMedCrossRef

22.

Vanhorebeek I, De Vos R, Mesotten D et al (2005) Strict blood glucose control with insulin in critically ill patients protects hepatocytic mitochondrial ultrastructure and function. Lancet 365:53–59PubMedCrossRef

23.

Langouche L, Vanhorebeek I, Vlasselaers D et al (2005) Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115:2277–2286PubMedCrossRef

24.

Weekers F, Giuletti A-P, Michalaki M et al (2003) Endocrine and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 144:5329–5338PubMedCrossRef

25.

Mesotten D, Swinnen JV, Vanderhoydonc F et al (2004) Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89:219–226PubMedCrossRef

26.

Hansen TK, Thiel S, Wouters PJ et al (2003) Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients, as indicated by circulating mannose-binding lectin and C-reactive protein levels. J Clin Endocrinol Metab 88:1082–1088PubMedCrossRef

27.

Vanhorebeek I, Peeters RP, Vander Perre S et al (2006) Cortisol response to critical illness: effect of intensive insulin therapy. J Clin Endocrinol Metab 91:3803–3813PubMedCrossRef

28.

Van Cromphaut S, Wilmer A, Van den Berghe G (2007) Management of sepsis. N Engl J Med 356:1179–1181; author reply 1181–1182PubMed

29.

Vriesendorp TM, DeVries JH, van Santen S et al (2006) Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med 34:26714–2718

30.

Mackenzie I, Ingle S, Zaidi S et al (2006) Hypoglycemia? So what! Intensive Care Med 32:620–621CrossRef

31.

Finney SJ, Zekveld C, Elia A et al (2003) Glucose control and mortality in critically ill patients. J Am Med Assoc 290:2041–2047CrossRef

32.

Langouche L, Vander Perre S, Wouters P, D’Hoore A, Hansen TK, Van den Berghe G (2007) Effect of intensive insulin therapy on insulin sensitivity in the critically ill. J Clin Endocrinol Metab 92:3890–3897PubMedCrossRef

33.

Malhotra A (2006) Intensive insulin in intensive care. N Engl J Med 354:516–518PubMedCrossRef

34.

Jolliet P, Pichard C, Biolog G et al (1998) Enteral nutrition in intensive care patients: a practical approach. Intensive Care Med 24:848–859PubMedCrossRef

35.

Impact of early parenteral nutrition completing enteral nutrition in adult critically ill patients (EPaNIC study—ClinicalTrials.gov Identifier: NCT00512122), available at http://clinicaltrials.gov/ct/show/NCT00512122, accessed 24 September 2007

Titel: Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l
verfasst von: G. Van den Berghe
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0878-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

N of 1 trials in diabetes: making individual therapeutic decisions

Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand

A potential role for skeletal muscle caveolin-1 as an insulin sensitivity modulator in ageing-dependent non-obese type 2 diabetes: studies in a new mouse model

Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy

The relationship between admission blood glucose levels and hospital mortality

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin